스킵네비게이션

Enterprise Together with KSC

Company Overview
AbTis 3rd Generation ADC over 1st & 2nd Generation ADCs Drug Antibody Ratio Control(DAR 2, 4, 6, 8) No Mutation or Modification on Antibody Site-Specific Conjugation to specific Lysine

Sectors

  • Innovative new medicine, biopharmaceuticals, Antibody Drug Conjugate(ADC)

Project Summary

  • Development of antibody drug conjugate (ADC) through linker platform technology that enables antibody site-selective payload conjugation

Business Model

  • Revenue model licensing out(ADC or ADC platform technology)
  • Key Customer Pharmaceutical companies, antibody development companies
Major Performance

  • Sales

    • N/A

  • Investment

    • $17.6 million
    • Stonebridge Ventures, K2 Investment Partners, CKD Venture Capital, Timefolio Asset Management, Prodigy Investment, AJU IB Investment, KDB Capital, Kingo Investment Partners

  • Employees

    • 2021-20

  • Patent

    • Application 18
    • Registration 12
Overseas Expansion

Stage

Preparing for overseas expansion

Status

Building a global network

Short-term goals in three years
  • Entered phase 1 clinical trial of main ADC pipeline
  • At least one licensing out
Products / Services
1 2
Target Country
Israel
Date of Establishment
August 01, 2016
  • Email
    info@abtis.co.kr info@abtis.co.kr
  • Website
    http://abtis.co.kr/ http://abtis.co.kr/
  • Location
    Venture Valley2 A-815, Sanup-ro 156, 142-10 Kwonsun-gu, Suwon-si, Gyeonggi-do, 16648,Rep. of KOREA
  • CEO
    Sang Jeon Chung
  • Founder’s Background
    • SungKyunKwan University(Samsung Group), Professor in Pharmacy
    • Dongguk University, Professor in Chemistry
    • KRIBB, Senior Researcher
    • Harvard University, Post Doctoral
    • The Scripps Research Institute, Visiting Researcher
목록